Clinical Trial

A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
The study was terminated early due to discontinuation of development of the investigational program.
Summary
The goal of this clinical trial is to learn more about the side effects and best dose of AXN-2510 in adults with advanced solid tumors. The main questions it aims to answer are: * What are the side effects of AXN-2510? * Which is the best tolerated dose of AXN-2510? * How long does AXN-2510 stay in your body? Participants will receive AXN-2510 every 3 weeks. Participants will visit the clinic for checkups and tests several days during the first and third doses, and once every 3 weeks for other doses.
Protocol Amendment History 5 changes
critical Trial terminated 2026-05-07
critical Reason stopped changed: — → The study was terminated early due to discontinuation of development of the investigational program. 2026-05-07
notable Enrollment reduced: 52 -> 3 participants 2026-05-07
notable Primary completion moved earlier: 2026-07 -> 2026-04-16 2026-05-07
minor Completion moved earlier: 2027-05-15 -> 2026-04-16 2026-05-07
Trial Details
NCT Number NCT07159828
Lead Sponsor Axion Bio, Inc
Collaborators: Instil Bio
Conditions Solid Tumor, Adult
Enrollment 3 participants
Start Date 2025-09-15
Primary Completion 2026-04-16 (estimated)
Study Completion 2026-04-16 (estimated)
Updated on ClinicalTrials.gov 2026-05-06